company background image
NOVO B logo

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

DKK 409.55

Market Cap

DKK 1.8t

7D

-10.4%

1Y

-52.9%

Updated

10 Apr, 2025

Data

Company Financials +

Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 1.8t

NOVO B Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details

NOVO B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends4/6

Rewards

Trading at 65.8% below our estimate of its fair value

Earnings are forecast to grow 13.18% per year

Earnings grew by 20.7% over the past year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Unstable dividend track record

Has a high level of debt

Significant insider selling over the past 3 months


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

NOVO B logo
Novo Nordisk
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts

Launch Of CagriSema And Catalent Expansion Will Drive Future Success

Key Takeaways Strategic acquisitions and capacity expansion are expected to enhance global manufacturing, supporting revenue growth through increased patient reach. Focus on innovative treatments and pipeline expansion aims to strengthen market position and could drive sustainable revenue and earnings growth.
View narrative
DKK 771.50
FV
46.9% undervalued intrinsic discount
16.14%
Revenue growth p.a.
8users have liked this narrative
0users have commented on this narrative
317users have followed this narrative
1 day ago author updated this narrative
NOVO B logo
Novo Nordisk
UN
Unike
Community Contributor

Novo Nordisk gears up for explosive growth in weight-loss and diabetes treatments

Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.
View narrative
DKK 1.04k
FV
60.5% undervalued intrinsic discount
10.00%
Revenue growth p.a.
16users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
about 1 month ago author updated this narrative
View Novo Nordisk Community

Novo Nordisk A/S Competitors

ALK-Abelló

CPSE:ALK B

DKK 30.4b

H. Lundbeck

CPSE:HLUN B

DKK 27.1b

AstraZeneca

LSE:AZN

UK£155.3b

Merck

NYSE:MRK

US$206.1b

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share PriceDKK 409.55
52 Week HighDKK 1,033.20
52 Week LowDKK 398.25
Beta0.25
1 Month Change-22.80%
3 Month Change-35.23%
1 Year Change-52.89%
3 Year Change1.12%
5 Year Change93.96%
Change since IPO15,096.67%

Recent News & Updates

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 07
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Recent updates

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 07
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Mar 14
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 28
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
author-image

Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike

Feb 13Are there any products or services that could move sales or earnings meaningfully?Most Immediate Catalyst (1–2 Years):Established GLP-1 Products:Ozempic & Rybelsus: driving robust sales and market pe

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
author-image

Expanding Horizons And Innovation Drive Bold Growth In Pharma's Global Landscape

Nov 07 Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach.

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D-10.4%-11.4%-8.3%
1Y-52.9%-20.0%-37.2%

Return vs Industry: NOVO B underperformed the Danish Pharmaceuticals industry which returned -20% over the past year.

Return vs Market: NOVO B underperformed the Danish Market which returned -37.2% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.8%
10% most volatile stocks in DK Market10.0%
10% least volatile stocks in DK Market3.6%

Stable Share Price: NOVO B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: NOVO B's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192376,826Lars Jorgensenwww.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capDKK 1.82t
Earnings (TTM)DKK 100.99b
Revenue (TTM)DKK 290.40b

18.0x

P/E Ratio

6.3x

P/S Ratio

Is NOVO B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
RevenueDKK 290.40b
Cost of RevenueDKK 43.56b
Gross ProfitDKK 246.84b
Other ExpensesDKK 145.86b
EarningsDKK 100.99b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 07, 2025

Earnings per share (EPS)22.75
Gross Margin85.00%
Net Profit Margin34.78%
Debt/Equity Ratio66.9%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

50%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/10 04:32
End of Day Share Price 2025/04/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 69 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research